Tyrosine Kinase
- IGFBR(1)
- Bcr-Abl(73)
- Ack1(4)
- Axl(6)
- ALK(61)
- BMX Kinase(4)
- Broad Spectrum Protein Kinase Inhibitor(11)
- c-FMS(35)
- c-Kit(65)
- c-MET(91)
- c-RET(7)
- CSF-1R(3)
- DDR1/DDR2 Receptor(1)
- EGFR(251)
- EphB4(2)
- FAK(34)
- FGFR(104)
- FLT3(102)
- HER2(19)
- IGF1R(33)
- Insulin Receptor(45)
- IRAK(32)
- ITK(12)
- Lck(2)
- LRRK2(23)
- PDGFR(117)
- PTKs/RTKs(5)
- Pyk2(6)
- ROR(41)
- Spleen Tyrosine Kinase (Syk)(35)
- Src(105)
- Tie-2 (3)
- Trk(37)
- VEGFR(203)
- Kinase(0)
- Discoidin Domain Receptor(15)
- DYRK(26)
- Ephrin Receptor(13)
- ROS(15)
- RET(34)
- TAM Receptor(28)
Products for Tyrosine Kinase
- Cat.No. Product Name Information
- GC68030 FAK-IN-7
- GC64836 Famitinib Famitinib (SHR1020), an orally active multi-targeted kinase inhibitor, inhibits the activity of c-kit, VEGFR-2 and PDGFRβ with IC50 values of 2.3 nM, 4.7 nM and 6.6 nM, respectively. Famitinib exerts powerful antitumor activity in human gastric cancer cells and xenografts. Famitinib triggers apoptosis.
- GC38437 Fangchinoline An alkaloid with diverse biological activities
- GC63395 FGFR-IN-1 FGFR-IN-1 is a potent FGFR inhibitor with an IC50 of <100 nM for FGFR1, FGFR2, and FGFR3, respectively (patent US20130338134A1, example 219).
- GC65212 FGFR1/DDR2 inhibitor 1 FGFR1/DDR2 inhibitor 1 is an orally active inhibitor of fibroblast growth factor receptor 1 (FGFR1) and discoindin domain receptor 2 (DDR2), with IC50 values of 31.1 nM and 3.2 nM, respectively. Antitumor activity.
- GC64475 FGFR2-IN-2 FGFR2-IN-2 (Compound 38) is a selective FGFR2 inhibitor with IC50s of 389, 29, and 758 nM for FGFR1, FGFR2, and FGFR3, respectively.
- GC65992 FGFR2-IN-3 FGFR2-IN-3 is an orally active selective inhibitor of FGFR2.
- GC65991 FGFR2-IN-3 hydrochloride FGFR2-IN-3 hydrochloride is an orally active selective inhibitor of FGFR2.
- GC19155 FGFR4-IN-1 FGFR4-IN-1 is a potent inhibiotr of FGFR4 with IC50 of 0.7 nM.
- GC62602 FGFR4-IN-5 FGFR4-IN-5 is a potent and selective covalent FGFR4 inhibitor with an IC50 of 6.5 nM. FGFR4-IN-5 exhibits strong anti-tumor activity in vivo and can be used for hepatocellular carcinoma research.
- GC50051 FIIN 1 hydrochloride FIIN 1 hydrochloride is a potent, irreversible, selective FGFR inhibitor. FIIN 1 hydrochloride binds to FGFR1/2/3/4 and Flt1/4 with Kds of 2.8/6.9/5.4/120 nM and 32/120 nM respectively. The biochemical IC50s of FIIN 1 hydrochloride are 9.2, 6.2, 11.9, and 189 nM against FGFR1/2/3/4, respectively.
- GC17323 FIIN-2 Irreversible inhibitor of FGFR
- GC36044 FIIN-3 FIIN-3 is an irreversible inhibitor of FGFR with an IC50 of 13.1, 21, 31.4, and 35.3 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.
- GC47350 Finasteride-d9 An internal standard for the quantification of finasteride
- GC14807 Fingolimod(FTY720) Fingolimod (FTY720) HCl (FTY720), an analog of sphingosine, is a potent sphingosine 1-phosphate (S1P) receptors modulator.
- GC43676 FLT3 Inhibitor III FLT3 Inhibitor III is a potent inhibitor of Fms-like tyrosine kinase 3 (FLT3; IC50 = 50 nM).
- GC32968 FLT3-IN-1
- GC33242 FLT3-IN-1 Succinate
- GC63936 FLT3-IN-10 FLT3-IN-10 (compound 7c) is a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3). FLT3-IN-10 has the potential for the treatment of FLT3-mutated acute myeloid leukemia (AML).
- GC65984 FLT3-IN-16 FLT3-IN-16 is a potent FLT3 inhibitor with an IC50 of 1.1 μM. FLT3-IN-16 can be used for researching acute myeloid leukemia.
- GC19158 FLT3-IN-2 FLT3-IN-2 is a FLT3 inhibitor with IC50 of < 1 uM, detailed information refer to WO 2012158957 A2 and WO 2007013896.
-
GC19772
FLT3-IN-3
FLT3-IN-3 is a potent FLT3 inhibitor with IC50s of 13 and 8 nM for FLT3 WT and FLT3 D835Y, respectively.
- GC36055 FLT3-IN-4 FLT3-IN-4 is a potent and orally effective Fms-like tyrosine receptor kinase 3 (FLT3; IC50=7 nM) inhibitor for treating acute myelogenous leukemia.
- GC36056 FLT3-IN-6 FLT3-IN-6 is a potent and selective inhibitor of FLT3-ITD (FLT3 mutation) with an IC50 of 1.336 nM.
- GC32867 Flumatinib (HHGV678) Flumatinib (HHGV678) (HHGV678) is an orally available, selective inhibitor of Bcr-Abl. Flumatinib (HHGV678) inhibits c-Abl, PDGFRβ and c-Kit with IC50s of 1.2 nM, 307.6 nM and 665.5 nM, respectively.
- GC13914 Flumatinib mesylate PDGRFβ inhibitor
- GC33049 FN-1501 FN-1501 is a potent inhibitor of FLT3 and CDK, with IC50s of 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively. FN-1501 has anticancer activity.
- GC15735 Foretinib (GSK1363089) Foretinib (GSK1363089) is a multi-target tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.
- GN10527 Formononetin
- GC64708 Fosgonimeton
- GC11044 Fostamatinib (R788) Fostamatinib (R788) (R788) is the oral prodrug of the active compound R406.
- GC10355 Fruquintinib(HMPL-013) Fruquintinib(HMPL-013) (HMPL-013) is a highly potent and selective VEGFR 1/2/3 inhibitor with IC50s of 33, 0.35, and 35 nM, respectively.
- GN10540 Fumalic acid
- GC12178 G-749 FLT3 inhibitor
- GC47392 Ganglioside GM1 Mixture (ovine) (ammonium salt) A mixture of ganglioside GM1
- GC43732 Ganglioside GM3 Mixture (sodium salt) Ganglioside GM3 is a monosialoganglioside that demonstrates antiproliferative and proapoptotic effects in tumor cells by modulating cell adhesion, proliferation, and differentiation.
- GA21893 Gastric Inhibitory Polypeptide (1-30) amide (porcine) Gastric Inhibitory Polypeptide (1-30) amide (porcine) is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42).
- GA21894 Gastric Inhibitory Polypeptide (3-42) (human) Gastric Inhibitory Polypeptide (3-42) (human) acts as a glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist, moderating the insulin secreting and metabolic actions of GIP in vivo.
-
GC16737
Gefitinib (ZD1839)
Gefitinib (ZD1839), is a potent EGFR-TKI (EGFR tyrosine kinase inhibitor)
- GC60868 Gefitinib D8 Gefitinib D8 (ZD1839 D8) is a deuterium labeled Gefitinib. Gefitinib is an EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells.
- GC14295 Gefitinib hydrochloride An EGFR inhibitor
- GC19509 Gefitinib-based PROTAC 3 A VHL-recruiting PROTAC
- GC47395 Gefitinib-d6 An internal standard for the quantification of gefitinib
- GC65478 Gemnelatinib Gemnelatinib is a tyrosine kinase inhibitor (WO2018077227, implementation example 1). Gemnelatinib can be used for the research of cancer.
-
GC14102
Genistein
Genistein is an isoflavone belonging to the flavonoid group of compounds and is found in a number of plants.
- GC47398 Genistein-d4 An internal standard for the quantification of genistein
- GC31842 GENZ-882706 (RA03546849) GENZ-882706 (RA03546849) is a potent colony stimulating factor-1 receptor (CSF-1R) Inhibitor extracted from patent WO 2017015267A1.
- GC30295 GENZ-882706(Raceme) (GENZ-882706 racemate) GENZ-882706(Raceme) (GENZ-882706 racemate) is the racemate of GENZ-882706.
- GC62633 GGTI-2154 GGTI-2154 is a potent and selective inhibitor of geranylgeranyltransferase I (GGTase I), with an IC50 of 21 nM. GGTI-2154 shows more than 200-fold selectivity for GGTase I over FTase (IC50=5600 nM). GGTI-2154 can be used for the research of cancer.
-
GC19482
Gilteritinib
Gilteritinib (ASP2215, Xospata) for relapsed and /or refractory AML (R/R AML).
- GC36135 Gilteritinib hemifumarate Gilteritinib (ASP2215) hemifumarate is a potent and ATP-competitive FLT3/AXL inhibitor with IC50 of 0.29 nM/0.73 nM, respectively.
- GN10156 Ginsenoside Rb1
- GC31706 Ginsenoside Rg5 A ginsenoside with diverse biological activities
- GC61569 GIP (1-30) amide, porcine TFA GIP (1-30) amide, porcine TFA is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42).
- GC60175 GIP (1-30) amide,Human acetate GIP (1-30) amide,human acetate is a glucose-dependent insulinotropic polypeptide (GIP) fragment.
- GC61741 GIP, human TFA GIP, human TFA, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion.
- GC19166 Glesatinib hydrochloride Glesatinib hydrochloride is an inhibitor of the MET and Axl receptor tyrosine kinase pathways, which drive tumour growth when altered.
- GC64947 Glumetinib Glumetinib (SCC244) is a highly selective, orally bioavailable, ATP-competitive c-Met inhibitor with an IC50 of 0.42 nM. Glumetinib has greater than 2400-fold selectivity for c-Met over those 312 kinases evaluated, including the c-Met family member RON and highly homologous kinases Axl, Mer, TyrO3. Antitumor activity.
- GC36167 GMB-475 GMB-475 is a degrader of BCR-ABL1 tyrosine kinase based on PROTAC, overcoming BCR-ABL1-dependent drug resistance. GMB-475 targets BCR-ABL1 protein and recruits the E3 ligase Von Hippel Lindau (VHL), resulting in ubiquitination and subsequent degradation of the oncogenic fusion protein.
- GC31871 GNE-0946 GNE-0946 is a potent and selective RORγ( RORc) agonist with an EC50 value of 4 nM for HEK-293 cell.
- GC32053 GNE-4997 GNE-4997 is a potent and selective interleukin-2-inducible T-cell kinase (ITK) inhibitor with a Ki of 0.09 nM, and the correlation between the basicity of solubilizing elements in GNE-4997 and off-target antiproliferative effects reduces cytotoxicity.
- GC33882 GNE-6468 GNE-6468 is a highly potent and selective RORγ (RORc) inverse agonist with an EC50 value of 13 nM for HEK-293 cell.
- GC12121 GNE-7915 Potent and selective LRRK2 inhibitor
- GC36171 GNE-7915 tosylate GNE-7915 tosylate is a potent, selective and brain-penetrant inhibitor of LRRK2 with an IC50 of 9 nM.
- GC13868 GNE-9605 LRRK2 inhibitor, brain-penetrant, potent and selective
- GC15196 GNE0877 Potent and selective LRRK2 inhibitor
- GC10858 GNF 2 Bcr-Abl inhibitor
- GC15079 GNF 5 Bcr-Abl inhibitor
- GC16343 GNF-5837 Pan-Trk inhibitor
-
GC10607
GNF-7
Type II Bcr-Abl inhibitor
- GC64724 GNF2133 GNF2133 is a potent, selective and orally active DYRK1A inhibitor with IC50s of 0.0062, >50 ?M for DYRK1A and GSK3β, respectively.
- GC64725 GNF2133 hydrochloride GNF2133 hydrochloride is a potent, selective and orally active DYRK1A inhibitor with IC50s of 0.0062, >50 ?M for DYRK1A and GSK3β, respectively.
- GC38787 GNF4877 GNF4877 is a potent DYRK1A and GSK3β inhibitor with IC50s of 6?nM and 16?nM, respectively, which leads to blockade of nuclear factor of activated T-cells (NFATc) nuclear export and increased β-cell proliferation (EC50 of 0.66?μM for mouse β (R7T1) cells).
- GC17715 Golvatinib (E7050) Golvatinib (E7050) (E-7050) is a potent dual inhibitor of both c-Met and VEGFR2 kinases with IC50s of 14 and 16 nM, respectively.
- GC16430 GS-9973 GS-9973 (GS-9973) is an orally bioavailable, selective Syk inhibitor with an IC50 of 7.7 nM.
- GC50429 GSK 143 Syk inhibitor
- GC50156 GSK 2250665A Itk inhibitor
- GC36194 GSK-626616 GSK-626616 is a potent, orally bioavailable inhibitor of DYRK3 (IC50=0.7 nM).
- GC68447 GSK143 dihydrochloride
- GC12273 GSK1838705A IGF-IR/IR/ALK inhibitor, ATP-competitive
- GC17612 GSK1904529A Selective IGF-1R/IR inhibitor
- GC64888 GSK215 GSK215 is a potent and selective PROTAC focal adhesion kinase (FAK) degrader with a pDC50 of 8.4. GSK215 is designed by a binder for the VHL E3 ligase and the FAK inhibitor VS-4718. GSK215 induces rapid and prolonged FAK degradation, giving a long-lasting effect on FAK levels and a marked pharmacokinetic/pharmacodynamics (PK/PD) disconnect.
- GC19179 GSK2256098 GSK2256098 is a selective FAK kinase inhibitor, which inhibits growth and survival of pancreatic ductal adenocarcinoma cells.
- GC18049 GSK2578215A LRRK2 inhibitor
- GC64889 GSK2646264 GSK2646264 (Compound 44) is a potent and selective spleen tyrosine kinase (SYK) inhibitor with a pIC50 of 7.1.
- GC13905 GSK2981278 RORγ-selective inverse agonist
- GC18492 GSK3179106 A RET kinase inhibitor
- GC18591 GSK805 GSK805 is a potent, orally bioavailable retinoid-related orphan receptor gamma t (RORγt) inverse agonist that interacts with the receptor's putative ligand binding domain without exerting significant effects on DNA binding.
- GC64875 Gunagratinib Gunagratinib (ICP-192) is a low toxicity and orally active pan-FGFR (fibroblast growth factor receptors) inhibitor that potently and selectively inhibits FGFR activities irreversibly by covalent binding. Gunagratinib can be used for the research of cancer.
- GC33041 Gusacitinib (ASN-002) Gusacitinib (ASN-002) (ASN-002) is an orally active and potent dual inhibitor of spleen tyrosine kinase (SYK) and janus kinase (JAK) with IC50 values of 5-46 nM. Gusacitinib (ASN-002) has anti-cancer activity in both solid and hematological tumor types.
- GC15927 GW 583340 dihydrochloride dual EGFR/ErbB2 tyrosine kinase inhibitor
- GC17286 GW2580 CFMS kinase/CSF-1R inhibitor,selective and ATP-competitive
- GC14123 GW441756 TrkA inhibitor,potent and selective
- GC36203 GW806742X GW806742X, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a Kd of 9.3 μM.
- GC61454 GW806742X hydrochloride GW806742X hydrochloride, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a Kd of 9.3 μM. GW806742X hydrochloride has activity against VEGFR2 (IC50=2 nM). GW806742X hydrochloride retards MLKL membrane translocation and inhibits necroptosis.
- GC10915 GZD824 Olverembatinib (GZD824) dimesylate is a potent and orally active pan-Bcr-Abl inhibitor. GZD824 potently inhibits a broad spectrum of Bcr-Abl mutants. GZD824 strongly inhibits native Bcr-Abl and Bcr-AblT315I with IC50s of 0.34 nM and 0.68 nM, respectively. GZD824 has antitumor activity.
- GC33201 GZD856 GZD856 formic is a potent and orally active PDGFRα/β inhibitor, with IC50s of 68.6 and 136.6 nM, respectively. GZD856 formic is also a Bcr-AblT315I inhibitor, with IC50s of 19.9 and 15.4?nM for native Bcr-Abl and the T315I mutant. GZD856 formic has antitumor activity.
- GC62453 GZD856 formic GZD856 formic is a potent and orally active PDGFRα/β inhibitor, with IC50s of 68.6 and 136.6 nM, respectively. GZD856 formic is also a Bcr-AblT315I inhibitor, with IC50s of 19.9 and 15.4?nM for native Bcr-Abl and the T315I mutant. GZD856 formic has antitumor activity.
- GC17923 H-7 dihydrochloride H-7 dihydrochloride is a potent PKC (protein kinase C) inhibitor. At 100 μM, H-7 dihydrochloride completely inhibits both TPA (skin tumour promoter, 12-O-tetradecanoylphorbol-13-acetate) and phospholipase C-induced ODC (ornithine decarboxylase).
- GC11420 H-9 dihydrochloride Protein kinase inhibitor